VTGN 3.62 ▼ -1.90% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    VistaGen Therapeutics Inc...

    NASDAQ: VTGN · Real-Time Price · USD
    3.62
    -0.07 (-1.90%)
    At close: Sep 04, 2025, 3:59 PM
    3.72
    2.72%
    Pre-market: Sep 05, 2025, 08:53 AM EDT
    -1.90%
    Bid 3.6
    Market Cap 111.06M
    Revenue (ttm) 646K
    Net Income (ttm) -55.78M
    EPS (ttm) -1.79
    PE Ratio (ttm) -2.02
    Forward PE -2.28
    Analyst n/a
    Ask 3.77
    Volume 346,325
    Avg. Volume (20D) 436,604
    Open 3.84
    Previous Close 3.69
    Day's Range 3.61 - 3.88
    52-Week Range 1.90 - 3.88
    Beta 0.55

    About VTGN

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol VTGN
    Website n/a
    Full Company Profile

    Next Earnings Release

    VistaGen Therapeutics Inc. is scheduled to release its earnings on Nov 6, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription
    news image

    4 weeks ago · seekingalpha.com

    Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call Transcript

    Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q1 2026 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Cynthia Lynn Anderson - VP & Chief Financial Officer Joshua S. Prince - Chief...

    news image

    4 weeks ago · fool.com

    Vistagen (VTGN) Q1 R&D Expense Jumps 54%

    Vistagen (VTGN) Q1 R&D Expense Jumps 54%

    news image

    4 weeks ago · zacks.com

    VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates

    VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.47 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.35 per share a year ago.

    news image

    4 weeks ago · businesswire.com

    Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...

    news image

    1 month ago · businesswire.com

    Vistagen to Present at the BTIG Virtual Biotechnology Conference

    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...

    news image

    1 month ago · businesswire.com

    Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...

    news image

    2 months ago · businesswire.com

    Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...

    news image

    2 months ago · seekingalpha.com

    Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript

    Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q4 2025 Earnings Conference Call June 17, 2025 5:00 PM ET Company Participants Cynthia Lynn Anderson - VP & Chief Financial Officer Mark Adrian McPartland - ...

    news image

    2 months ago · businesswire.com

    Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...

    news image

    2 months ago · businesswire.com

    Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...

    Add to Watchlist